Immix Biopharma Net Worth
Immix Biopharma Net Worth Breakdown | IMMX |
Immix Biopharma Net Worth Analysis
Immix Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Immix Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Immix Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Immix Biopharma's net worth analysis. One common approach is to calculate Immix Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Immix Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Immix Biopharma's net worth. This approach calculates the present value of Immix Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Immix Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Immix Biopharma's net worth. This involves comparing Immix Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Immix Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Immix Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immix Biopharma's net worth research are outlined below:
| Immix Biopharma is way too risky over 90 days horizon | |
| Immix Biopharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (21.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immix Biopharma currently holds about 18.4 M in cash with (14.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Immix Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Immix Biopharma Highlights Promising Safety Profile for NXC-201 IMMX Stock News |
Immix Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immix Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immix Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Immix Biopharma Target Price Consensus
Immix target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Immix Biopharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Immix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Immix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Immix Biopharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationImmix Biopharma Target Price Projection
Immix Biopharma's current and average target prices are 2.97 and 7.00, respectively. The current price of Immix Biopharma is the price at which Immix Biopharma is currently trading. On the other hand, Immix Biopharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Immix Biopharma Market Quote on 20th of July 2025
Target Price
Analyst Consensus On Immix Biopharma Target Price
Know Immix Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immix Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immix Biopharma backward and forwards among themselves. Immix Biopharma's institutional investor refers to the entity that pools money to purchase Immix Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Commonwealth Equity Services Inc | 2025-03-31 | 17 K | Xtx Topco Ltd | 2025-03-31 | 12.8 K | The Colony Group Llc | 2025-03-31 | 11.9 K | Blackrock Inc | 2025-03-31 | 11.8 K | Fny Investment Advisers, Llc | 2025-03-31 | 11.2 K | Ubs Group Ag | 2025-03-31 | 10.1 K | Tower Research Capital Llc | 2025-03-31 | 471 | Wells Fargo & Co | 2025-03-31 | 330 | Bank Of America Corp | 2025-03-31 | 120 | Bleichroeder Lp | 2025-03-31 | 850 K | Cable Car Capital Llc | 2025-03-31 | 779.4 K |
Follow Immix Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.8 M.Market Cap |
|
Project Immix Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.94) | (0.99) | |
| Return On Capital Employed | (1.59) | (1.51) | |
| Return On Assets | (0.94) | (0.99) | |
| Return On Equity | (1.63) | (1.55) |
When accessing Immix Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Immix Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immix Biopharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immix Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immix Biopharma. Check Immix Biopharma's Beneish M Score to see the likelihood of Immix Biopharma's management manipulating its earnings.
Evaluate Immix Biopharma's management efficiency
Immix Biopharma has return on total asset (ROA) of (0.5017) % which means that it has lost $0.5017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1234) %, meaning that it created substantial loss on money invested by shareholders. Immix Biopharma's management efficiency ratios could be used to measure how well Immix Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.99 in 2025. Return On Capital Employed is likely to rise to -1.51 in 2025. At this time, Immix Biopharma's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2.9 M in 2025, whereas Total Assets are likely to drop slightly above 14.2 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.47 | 0.27 | |
| Tangible Book Value Per Share | 0.47 | 0.27 | |
| Enterprise Value Over EBITDA | (2.12) | (2.22) | |
| Price Book Value Ratio | 4.70 | 4.93 | |
| Enterprise Value Multiple | (2.12) | (2.22) | |
| Price Fair Value | 4.70 | 4.93 | |
| Enterprise Value | 41.1 M | 24.8 M |
Immix Biopharma has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immix Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immix Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immix Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immix Biopharma time-series forecasting models is one of many Immix Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immix Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Immix Biopharma Earnings Estimation Breakdown
The calculation of Immix Biopharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Immix Biopharma is estimated to be -0.14875 with the future projection ranging from a low of -0.155 to a high of -0.1425. Please be aware that this consensus of annual earnings estimates for Immix Biopharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.15 Lowest | Expected EPS | -0.14 Highest |
Immix Biopharma Earnings Projection Consensus
Suppose the current estimates of Immix Biopharma's value are higher than the current market price of the Immix Biopharma stock. In this case, investors may conclude that Immix Biopharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Immix Biopharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 1 | 71.35% | 0.0 | -0.14875 | -0.69 |
Immix Biopharma Earnings per Share Projection vs Actual
Actual Earning per Share of Immix Biopharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Immix Biopharma predict the company's earnings will be in the future. The higher the earnings per share of Immix Biopharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Immix Biopharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Immix Biopharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Immix Biopharma should always be considered in relation to other companies to make a more educated investment decision.Immix Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Immix Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-07 | 2025-03-31 | -0.23 | -0.15 | 0.08 | 34 | ||
2025-02-26 | 2024-12-31 | -0.25 | -0.25 | 0.0 | 0 | ||
2024-11-09 | 2024-09-30 | -0.16 | -0.24 | -0.08 | 50 | ||
2024-08-11 | 2024-06-30 | -0.21 | -0.15 | 0.06 | 28 | ||
2024-05-09 | 2024-03-31 | -0.23 | -0.2244 | 0.0056 | 2 | ||
2024-03-29 | 2023-12-31 | -0.23 | -0.23 | 0.0 | 0 | ||
2023-11-13 | 2023-09-30 | -0.23 | -0.23 | 0.0 | 0 | ||
2023-08-11 | 2023-06-30 | -0.17 | -0.24 | -0.07 | 41 | ||
2023-05-12 | 2023-03-31 | -0.14 | -0.18 | -0.04 | 28 | ||
2023-03-27 | 2022-12-31 | -0.22 | -0.27 | -0.05 | 22 | ||
2022-11-09 | 2022-09-30 | -0.11 | -0.1102 | -2.0E-4 | 0 | ||
2021-12-17 | 2021-09-30 | 0 | -0.02 | -0.02 | 0 | ||
2021-09-17 | 2021-06-30 | 0 | -0.04 | -0.04 | 0 | ||
2021-06-30 | 2021-03-31 | 0 | -0.1815 | -0.1815 | 0 | ||
2021-03-31 | 2020-12-31 | 0 | -0.1815 | -0.1815 | 0 | ||
2020-09-30 | 2020-06-30 | 0 | -0.0345 | -0.0345 | 0 | ||
2020-06-30 | 2020-03-31 | 0 | -0.0394 | -0.0394 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.0394 | -0.0394 | 0 |
Immix Biopharma Corporate Management
| Denise Bruns | Head Regulatory | Profile | |
| JD MBA | CoFounder | Profile | |
| David Marks | Chief Therapy | Profile | |
| David MBBS | Chief Therapy | Profile | |
| Gabriel BA | CFO Director | Profile | |
| Gerhard Bauer | Head Manufacturing | Profile | |
| MD FFPM | Chief Development | Profile |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.